241 related articles for article (PubMed ID: 34435474)
1. Alitretinoin in the treatment of cutaneous T-cell lymphoma.
Kaemmerer T; Stadler PC; Helene Frommherz L; Guertler A; Einar French L; Reinholz M
Cancer Med; 2021 Oct; 10(20):7071-7078. PubMed ID: 34435474
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
4. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Janiga J; Kentley J; Nabhan C; Abdulla F
Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
[TBL] [Abstract][Full Text] [Related]
5. Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.
Anadolu RY; Birol A; Sanli H; Erdem C; Türsen U
Int J Dermatol; 2005 Jul; 44(7):559-65. PubMed ID: 15985024
[TBL] [Abstract][Full Text] [Related]
6. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK; Montanari F; Foss F; Reddy N
Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.
Devata S; Wilcox RA
Am J Clin Dermatol; 2016 Jun; 17(3):225-37. PubMed ID: 26923912
[TBL] [Abstract][Full Text] [Related]
8. Treatment of cutaneous T-cell lymphoma with oral alitretinoin.
Kapser C; Herzinger T; Ruzicka T; Flaig M; Molin S
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):783-8. PubMed ID: 25175592
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
10. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
11. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
Trager MH; Geskin LJ
G Ital Dermatol Venereol; 2019 Dec; 154(6):681-695. PubMed ID: 31859467
[TBL] [Abstract][Full Text] [Related]
12. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous T-cell Lymphomas: A Single-center Retrospective Analysis.
Kaemmerer T; Guertler A; Clanner-Engelshofen BM; Fuchs C; French LE; Reinholz M
Acta Dermatovenerol Croat; 2023 Dec; 31(4):184-190. PubMed ID: 38651844
[TBL] [Abstract][Full Text] [Related]
14. Acitretin for the treatment of cutaneous T-cell lymphoma.
Cheeley J; Sahn RE; DeLong LK; Parker SR
J Am Acad Dermatol; 2013 Feb; 68(2):247-54. PubMed ID: 22917895
[TBL] [Abstract][Full Text] [Related]
15. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
[TBL] [Abstract][Full Text] [Related]
16. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
[TBL] [Abstract][Full Text] [Related]
17. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
18. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
[TBL] [Abstract][Full Text] [Related]
20. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]